PureTech Health

As we enter this season of gratitude, we’re reflecting on the many reasons we’re thankful at PureTech. Happy Thanksgiving from all of us at PureTech!

LONDON BIO was a roaring success this week. Our 6th edition, taking place alongside Jefferies Healthcare Conference 2024 in London on Tuesday 19th November. Yasmin Siraj of BACKED VC Jack O'Meara and Emma Tinsley of Weatherden hosted over 160 guests aboard the HMS Wellington for Afternoon Tea - a truly unique break in conference and side event schedules. ?"At #LONDONBIO we bring in game changers in the industry to share their wisdom and experiences with our diverse community, and it was great to do so during London life sciences week and see folks from all over the over the globe attend." - Yasmin, our biotech investment manager? We heard three lightning talks from six esteemed speakers: Otello Stampacchia (Omega Funds), Bharatt Chowrira (PureTech Health), Luba Greenwood, J.D. (Gallop Oncology), Sutha Satkunarajah (Flagship Pioneering), Anta Gkelou (Sofinnova Partners), Najat Khan, PhD (Recursion). We operate with Chatham House rules so will share only a few topics discussed (be there for the next one in Q1 2025!): ?? We heard from the engaging Otello, who has invested in companies that have launched 50 drugs thus far, about a range of topics: one of his most memorable success stories; his mindset regarding building exceptional teams; and his discipline regarding when to invest in and exit from emerging technologies along the Gartner hype cycle. ?? Bharatt, Najat, and Sutha delved into how their companies span the continental divide between the US and UK and dug into how they think about retaining right to win via creative business models such as the hub-and-spoke model, relying on human data, thinking carefully about when to form partnerships to accelerate development, and retaining laser focus on areas with they largest unmet medical need and market size. ?? Lastly, Luba and Anta provided a fresh perspective on the inherent challenges of developing computationally enabled biotech companies from a cultural perspective, digging into the contrasting mindsets, compensations, and comforts of engineers vs scientists and the conflicts that can result. Our evening was made possible by our partners that serve as true enablers in the biotech ecosystem Amazon Web Services (AWS) (Alex Merwin, Natalie Holman-Shepherd) JonesTrading (James O'Neill, Jack Terranova, Rock Tonkel) Hlx Life Sciences (Max Eldridge), Canary Wharf Group (Mairi Dillon) Kadans Science Partner, Meru Advisors (Victoria Igumnova) and Morgan, Lewis & Bockius LLP (Luciana Griebel) And of course, thank you to THE WELLINGTON TRUST for hosting us, especially the wonderful team: Dominic, Alec, Fiona Sparkes and Clemmie Batty. ?? ?????We’ll be sharing updates on BACKED’s?LinkedIn?and?X @BackedVC, so do follow along to stay up to date and get updates for our next #LONDONBIO! #biotech #techbio #lifesciences #Jefferies24 Here are a couple of highlights from the evening in the meantime taken by ?? Tobie Charlton - more to follow.

Rob Costanzo, Ph.D., Head of Quality Assurance at PureTech, embodies our unwavering commitment to quality in everything we do. His leadership fosters a culture where excellence is non-negotiable, and his meticulous approach ensures that every therapeutic candidate we develop meets the highest standards. Rob approaches quality assurance the same way he approaches being an ice hockey goalie: by spotting risks early and intercepting potential setbacks before they have an impact. With over 20 years of experience in the pharmaceutical and biotech industries, Rob brings a winning combination of technical expertise, analytical development know-how, and a risk-based, phase-appropriate strategy that’s critical to advancing our programs successfully. His extensive experience with regulatory agencies like the FDA and EMA, coupled with his talent for solving complex challenges, makes him an invaluable leader in our mission to develop medicines for those most in need. Rob’s collaborative mindset and ability to leverage the collective expertise of his colleagues amplify the impact of his work, driving our programs forward with precision and care. Whether on the ice or in the lab, Rob’s commitment to excellence and problem-solving shines through – a true MVP in every sense! #GivingLifeToScience

We’re pleased to welcome Sandi Peterson to our Board of Directors! Ms. Peterson is a prominent and seasoned business leader with extensive experience driving innovation and operational excellence across leading global life sciences and consumer organizations. She has held a series of high-profile leadership roles over the course of her career, including serving as the lead independent director on the Microsoft Board of Directors and as the former Group Worldwide Chair for Johnson & Johnson.?https://bit.ly/4hYNVHK

Don’t miss a fireside chat with our CEO, Bharatt Chowrira, PhD, JD, and our President and Co-founder, Eric Elenko, PhD, at #JefferiesHealthcare tomorrow. A webcast will be available here: https://bit.ly/48Rrfop

Our CEO,?Bharatt Chowrira, PhD, JD, and President and Founder,?Eric Elenko, PhD, were recently featured on an episode of the?Biotech2050 podcast. In this comprehensive conversation, they discussed key insights from their professional journeys, the power of PureTech’s model to drive innovation for serious diseases and lessons in persistence from founding Karuna Therapeutics and inventing Cobenfy (formerly KarXT). ? To learn more about what makes PureTech’s approach to R&D unique and our vision for the future of medicine, listen to the full show here: https://bit.ly/48NgAeo

We’re pleased to announce Lauren White will join Seaport as our Chief Financial Officer! An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ: IMGN) prior to its acquisition by AbbVie (NYSE: ABBV) for $10.1 billion in 2024. As the CFO at ImmunoGen, she played a key role on the internal deal team, conducting thorough analysis and due diligence during the M&A process with multiple potential buyers, which ultimately led to the successful acquisition of the company by AbbVie. Additionally, Ms. White helped to maximize the successful commercial launch of ELAHERE?, a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. Ms. White brings over 22 years of experience to Seaport, where she will steer our capital financing strategy, accounting, FP&A and investor relations. Read the press release here: https://lnkd.in/eZ6KzfA2

We enjoy collaborating with incredibly talented people across fields, and we’re thrilled to support our friend and visionary, Mao Miyamoto, on her latest endeavor! On November 19th, Visionary Crossings will debut at LabCentral—an art-meets-science exhibition that captures the beauty of medical illustration through Mao’s unique journey from researcher to artist. Register here: https://bit.ly/40thwCB

We’re proud to see TIME recognize Cobenfy (formerly KarXT) as one of the top inventions of 2024. This therapy, invented and advanced by PureTech, is a testament to our commitment to developing breakthroughs that positively impact peoples’ lives. Our team remains dedicated to changing the treatment paradigm for patients facing devastating diseases, and Cobenfy’s recognition underscores the impact of our unique approach to drug development. #GivingLifeToScience

Our team has no shortage of talents—and that includes making spooky treats! Check out some highlights from our #Halloween Happy Hour this week, where we gathered around homemade ghostly goodies. #GivingLifeToScience